Abstract
Aim: Pharmacological therapy is a critical step in the management of individuals with Metabolic Syndrome (MetS) when lifestyle modifications can not to achieve the therapeutic goals. However, it is well-documented that other than weight loss, there is no single best therapy, and the treatment should consist of treatment of individual components of the MetS. The objective of this study was to investigate treatment of individual components of the MetS among a population –based sample of individuals with the clustering of those components of the MetS. Methods: A cross-sectional survey population-based examined a randomly collected sample of men and women living in three counties in central Iran participating in the baseline survey of a community –based program in 2000–2001. A questionnaire was completed for all participants to collect data regarding their demographic characteristics, medical status and history of medication use. In this study we determined the association between clustering of MetS components and pharmacological treatment of cardiovascular risk factors. Results: The most common pharmacologic agent received by individuals with MetS were beta blockers (72.8%) used for controlling high blood pressure, followed by lipid lowering agents (36%) without significant difference in trend of gender. Conclusion: Our results exhibited a high level of compliance with drug treatment. Further research is needed to better elucidate the compliance behavior of patients who have been diagnosed with MetS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
